Lonza Pharma & Biotech has opened its Collaborative Innovation Center (CIC) in the Haifa Life Science Park, Israel. The CIC acts as a hub for partnerships that aim to identify
Swiss gene editing company CRISPR Therapeutics and US-based regenerative medicine firm ViaCyte have formed a strategic alliance to discover, develop and commercialise stem cell therapies for diabetes patients.
The Cell and Gene Therapy Catapult (CGT Catapult) has announced a major investment in skills and capability training to help accelerate integration of cell and gene therapies into health services following their regulatory approval.